Captopril used in coronary artery disease and ischemic heart diseases reduced inflammation in vivo by lowering the level of IL-6 [11,12,18,19,22,34,35,36,37,38], and increasing the level of TGFβ since the macrophages are in vivo activated with drugs [37,38,39]. Here, TGFB1 is linked to coronary artery disorder.